Wide Ranks

CELU

Celularity Inc.

2.01

Top Statistics
Market Cap 44 M Forward PE -3.53 Revenue Growth 312.20 %
Current Ratio 0.26 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -264.30 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.09 Enterprise / Revenue 2.60 Price To Sales Trailing12 Months 1.04
Profitability
Profit Margins -264.30 % Operating Margins -84.02 %
Balance Sheet
Total Cash 467000 Total Cash Per Share 0.0210 Total Debt 67 M
Total Debt To Equity 242.19 Current Ratio 0.26 Book Value Per Share 1.27
All Measures
Short Ratio 36.00 % Message Board Id finmb_408304689 Shares Short Prior Month 680541
Return On Equity -1.54 City Florham Park Uuid acab037e-115e-3a22-b200-e5ce523f37ff
Previous Close 2.85 First Trade Date Epoch Utc 1 B Book Value 1.27
Beta 0.5090 Total Debt 67 M Volume 1 M
Price To Book 1.59 Last Split Date 1 B Fifty Two Week Low 1.30
Total Cash Per Share 0.0210 Total Revenue 42 M Shares Short Previous Month Date 1 B
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -84.02 %
Net Income To Common -112830000 Short Percent Of Float 0.2513 Implied Shares Outstanding 22 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 854710
Average Volume10days 854710 Total Cash 467000 Next Fiscal Year End 1 B
Revenue Per Share 2.10 Held Percent Insiders 0.5039 Ebitda Margins -84.11 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 2.85 Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000
Fifty Day Average 2.55 Open 2.85 Free Cashflow -33171750
State NJ Dividend Yield 0.00 % Return On Assets -0.1463
Time Zone Short Name EST Trailing Eps -104.78 Day Low 1.55
Address1 170 Park Avenue Shares Outstanding 22 M Price Hint 4
Target High Price 0.0000 Website https://www.celularity.com 52 Week Change -0.0563
Average Volume 1 M Forward Eps -0.5700 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 20.50 % Last Split Factor 1:10
Regular Market Day High 2.93 Is_sp_500 False Profit Margins -264.30 %
Debt To Equity 242.19 Fifty Two Week High 7.97 Day High 2.93
Shares Short 934457 Regular Market Open 2.85 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 2.60 Revenue Growth 312.20 %
Shares Percent Shares Out 0.0425 Operating Cashflow -20514000 Currency USD
Time Zone Full Name America/New_York Market Cap 44 M Is_nasdaq_100 False
Zip 07932 Quote Type EQUITY Industry Biotechnology
Long Name Celularity Inc. Regular Market Day Low 1.55 Held Percent Institutions 0.1485
Current Price 2.01 Enterprise To Ebitda -3.09 Financial Currency USD
Current Ratio 0.26 Gross Margins 60.24 % Industry Disp Biotechnology
Country United States Float Shares 10 M Two Hundred Day Average 3.31
Enterprise Value 111 M Price To Sales Trailing12 Months 1.04 Forward PE -3.53
Regular Market Volume 1 M Ebitda -35905000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases.

The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments.

Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.

In addition, the company is developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis.

Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand.

The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates.

Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.